Strategies

In the increasingly complex landscape of American civil litigation, a surge in mass tort claims has ushered in a contentious era where questionable lawsuits are multiplying against businesses, particularly those in the pharmaceutical, medical device, and consumer product sectors. This escalation is partly fueled by substantial financial investment from Wall Street, which eagerly backs these suits anticipating lucrative payouts from substantial settlements. Legal analysts note that a growing practice among plaintiffs’ attorneys is to generate an overwhelming number of claims, some of dubious validity, to pressure companies into settling en masse. This strategy relies heavily … Read more